Literature DB >> 10686447

Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia.

P Falke1, A M Elneihoum, K Ohlsson.   

Abstract

Activated leukocytes are believed to be involved in the pathogenesis and progression of atherosclerotic vascular disease and its consequences. In a 4-year observational follow-up study, we investigated whether markers for systemic leukocyte activation (leukocyte-derived inflammatory mediators) were related to cardiovascular mortality after cerebrovascular ischemia. Using enzyme-linked immunosorbent assays, we measured the plasma levels of soluble tumor necrosis factor receptor protein-1 (sTNFR-1), neutrophil gelatinase-associated lipocalin (NGAL) and neutrophil protease-4 (NP4) in 144 patients (90 stroke, 54 transient ischemic attack) 1-3 days after cerebral ischemia. During the 4 years of follow-up, 42 (29%) of the 144 patients died; 38 of cardiovascular causes and 4 of other causes. Patients with evidence of higher leukocyte activation (n = 47) had a higher 4-year cardiovascular mortality rate than those without evidence of leukocyte activation (n = 97; p < 0.005). Logistic regression analysis with age, sex and other significant predictors as covariates showed higher plasma levels of sTNFR1 and NGAL both to be significant independent predictors of cardiovascular mortality, the respective odds ratio, 95% confidence intervals, and p values being 2.0, 1.2-3.4, p < 0.01, and 3.6, 1.2-10.5, p = 0.02, respectively. We concluded that in patients with acute cerebral ischemia, plasma markers of leukocyte activation were significant predictors of long-term cardiovascular mortality. This may indicate an important role of activated leukocytes in the progression of these diseases. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686447     DOI: 10.1159/000016037

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  21 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study.

Authors:  Lori B Daniels; Elizabeth Barrett-Connor; Paul Clopton; Gail A Laughlin; Joachim H Ix; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2012-03-20       Impact factor: 24.094

3.  Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB.

Authors:  De-xiu Bu; Anne-Louise Hemdahl; Anders Gabrielsen; Jonas Fuxe; Chaoyong Zhu; Per Eriksson; Zhong-qun Yan
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 4.  Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.

Authors:  Yu Wang
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.

Authors:  Yalcin Solak; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Hilmi Umut Unal; Halil Yaman; Mahmut Gok; Hakki Cetinkaya; Abduzhappar Gaipov; Tayfun Eyileten; Sebahattin Sari; Ali Osman Yildirim; Halil Zeki Tonbul; Suleyman Turk; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-10-26       Impact factor: 2.370

6.  Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin.

Authors:  Alfonso Eirin; Monika L Gloviczki; Hui Tang; Andrew D Rule; John R Woollard; Amir Lerman; Stephen C Textor; Lilach O Lerman
Journal:  Nephrol Dial Transplant       Date:  2012-08-23       Impact factor: 5.992

Review 7.  Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review.

Authors:  Dinna N Cruz; Sergio Gaiao; Alan Maisel; Claudio Ronco; Prasad Devarajan
Journal:  Clin Chem Lab Med       Date:  2012       Impact factor: 3.694

8.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

Review 9.  Iron Reshapes the Gut Microbiome and Host Metabolism.

Authors:  Amy Botta; Nicole G Barra; Nhat Hung Lam; Samantha Chow; Kostas Pantopoulos; Jonathan D Schertzer; Gary Sweeney
Journal:  J Lipid Atheroscler       Date:  2021-03-10

Review 10.  Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders.

Authors:  Hongzhen Chen; Dewei Shang; Yuguan Wen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.